



**CAVA HEALTHCARE INC.
PRESS RELEASE**

**CAVA HEALTHCARE SUCCESSFULLY COMPLETES ITS 2020 ANNUAL MEETING
AND ANNOUNCES THE ADDITIONS OF ROSYLN RITCHIE-DERRIEN, TERRY
PEARSON, LEIGH ANDERSON AND BILL VANDER ZALM TO THE BOARD OF
DIRECTORS**

Vancouver, British Columbia, February 3, 2020 – Cava Healthcare Inc. (“Cava” or the “Company”) is pleased to announce the voting results from its Annual General and Special Meeting (“AGSM”) held on January 31, 2020 in Vancouver, British Columbia.

Shareholders holding a total of 1,782,002 common shares were represented by proxy at the AGSM, representing 91.07% of the votes attached to all outstanding common shares of the Company as at the record date. All matters submitted before the AGSM as set out in the Notice of the Meeting and Management Information Circular were passed by a show of hands at the AGSM, including:

1. setting the number of directors at seven (7). Dr. Wilfred Jefferies, Peter Field and Dr. Adrian Wade were re-elected. Roslyn Ritchie-Derrien, Dr. Terry Pearson, Dr. Leigh Anderson and William Vander Zalm were elected;
2. appointing Davidson & Company LLP, Chartered Professional Accountants, as the Company’s auditor for the ensuing year;
3. an ordinary resolution approving a new Stock Option Plan; and
4. an ordinary resolution approving the Company’s Advanced Notice

Mr. Sam Mercer did not stand for re-election at the AGSM. The Company would like to sincerely thank Mr. Mercer for his efforts and look forward to working with him as a member of Cava’s advisory board.

Ms. Roslyn Ritchie-Derrien is a successful business leader and philanthropist with a desire to be on the forefront of disease prevention enriching people’s lives through medical solutions that improve health and wellness. As the daughter of entrepreneur Dave Ritchie (Founder of Ritchie Brothers Auctioneers), a young Roslyn was immersed in the importance of hard work and the strategies underpinning successful business organizations. Ms. Ritchie-Derrien worked for Woodlands Hospital, Holy Family Hospital and sat on the board instrumental in building Canuck Place in Abbotsford. She currently owns and operates Lavender Eight in the Township of Langley, British Columbia, that specializes in growing the edible English lavender 'Hidcote' and Copperstone Ventures. Ms. Ritchie is a proud mother and grandmother who, in her spare time enjoys travel and is deeply rooted in the local equestrian community.

Dr. Terry Pearson is a scientist and entrepreneur, who is an emeritus professor in the Department of Biochemistry and Microbiology at the University of Victoria. He obtained his BSc in microbiology and PhD in immunology from the University of British Columbia where he worked with Professors Julia Levy and Douglas Kilburn and then as a postdoctoral researcher and staff scientist at the MRC Laboratory of Molecular Biology in Cambridge, England. Working together with Nobel Laureates, Caesar Milstein and Georges Köhler, at Cambridge he made a seminal contribution to medicine by generating the world's first commercial monoclonal antibody that laid the foundation for the exploitation of antibodies for diagnostics and therapeutics and many scientific applications. He subsequently joined the International Laboratory for Research on Animal Diseases (Nairobi, Kenya) where he introduced monoclonal antibody technology to Africa. For more than 35 years, his research has focused on tropical diseases (mainly African sleeping sickness), and translation of basic research discoveries into application to clinical diagnostic medicine in both the developed and developing world. In 2008, he co-founded SISCAPA Assay Technologies Inc. a clinical diagnostic company focused on measuring biomarker in complex Human samples. He currently serves on the boards of several private and public biotechnology companies.

Dr. N. Leigh Anderson is a scientist and entrepreneur who obtained his BA in Physics from Yale and a PhD in Molecular Biology from Cambridge University (England). He has published 170 papers and been granted 44 US Patents. He cofounded Large Scale Biology, a pioneering proteomics company that had its initial public offering in 2000, has served on the board of directors of Dade Behring (a global diagnostics company) and Luna Innovations (fiber-optic test and measurement). He received the 1983 Pittsburgh Analytical Chemistry Award; the 2008 Award for Outstanding Contributions to Animal Clinical Chemistry (AACC Division of Animal Clinical Chemistry); and the 2009 the Human Proteome Organization (HUPO) Distinguished Achievement Award in Proteomic Science.

William "Bill" Vander Zalm is an entrepreneur and retired politician based in British Columbia, Canada. Mr. Vander Zalm was elected to city council in Surrey in 1965 and became mayor in 1969. He was elected to the British Columbia Government in 1976 and served in the cabinet of Bill Bennett as Minister of Human Resources, then as Minister of Municipal Affairs and Transit and finally as Minister of Education. In these roles he planned and implemented the Vancouver's SkyTrain rapid transit system, the Vancouver Trade and Convention Centre, the construction of British Columbia Place Stadium, and the construction of the Coquihalla Highway. He became the 28th Premier of British Columbia, and served in this role from 1986 to 1991. During his term he hosted the world during the 1987 World Expo in Vancouver, British Columbia and helped establish British Columbia as leading global economy and a dragon of Pacific Rim commerce. He proudly holds the record of having every budget balanced in every one in his political positions, from beginning to end. He is also respected for his vast knowledge of horticulture and his success in the agriculture industry, including the Art Knapp Garden Centres. Mr. Vander Zalm is currently leading the South Fraser Community Rail group to establish environmentally conscious rapid transit alternatives.

Cava CEO and President says that *“This is an exciting time for Cava, the first of many inflection points. We have attracted a very strong board and management team who are motivated and focused”*.

For further information, please contact Brian Kaufman at info@cavahealthcare.ca or (604) 370-1757.

On Behalf of the Board of Directors

Peter Field
CEO and President

CAVA IS FOCUSED ON ENHANCING OPTIMAL HEALTH BY PREDICTING, PREVENTING AND ALLEVIATING DISEASE

Chronic and acute inflammation and poor immune function are at the core of developing disease. Cava is addressing this unmet healthcare challenge through isolation and characterization of novel compounds from medicinal plant extraction, creation of novel biomarkers for disease, and application of cutting-edge technologies to reverse inflammation and restore immune function to achieve optimal health.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this press release that are not purely historical are forward-looking statements and include statements regarding beliefs, plans, expectations and orientations regarding the future including, without limitation, matters related to the Company’s current and planned research and development programs, including in respect of the prosecution and maintenance of the patent portfolio, and the Company’s prospect of success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as “will”, “plans”, “expects”, “may”, “intends”, “anticipates”, “believes”, “proposes” or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward-looking statements are based on certain assumptions regarding the Company, including, without limitation, expected growth, results of operations and research and development activities (including in respect of the patent portfolio), results of operations, performance, industry trends, growth opportunities, and that the Company will be able to obtain the financing required to carry out its planned future business activities, retain and attract qualified research personnel and obtain and/or maintain the necessary intellectual property rights it needs to carry out its future business activities.

Actual results could differ from those projected in any forward-looking statements due to numerous factors including, risks and uncertainties relating to the actual results of research and development programs, the inability of the Company, to, among other things, protect its intellectual property, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, commercialize any therapeutic and diagnostic technologies, execute its proposed business plans, pursue business partnerships, complete its research and development programs as planned, and obtain the financing required to carry out its planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the Company’s industries may also adversely affect the future results or performance of the Company. These forward-looking statements are made as of the date of this press release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could

differ from those projected in these forward-looking statements. Although the Company believes that the statements, beliefs, plans, expectations, intentions and assumptions contained in this press release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations intentions or assumptions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by the Company from time-to-time. These reports and the Company's filings are available at www.sedar.com.

Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.